Increasing Demand for Personalized Medicine is Expected to Drive the Growth of the U.S. Polymerase Chain Reaction Market

The efficient delivery of personalized medicine is a key goal of healthcare. The demand for personalized healthcare is driven by the increasing incidence of chronic diseases, the aging population, and the need for more personalized and targeted treatments. The availability of new technologies such as digital PCR is enabling the development of more personalized medicines. It is important to have robust and reproducible means of gaining molecular information about a patient’s cancer that can be used to guide clinical decision-making to facilitate personalized medicine. A complete clinic-friendly single-instrument dPCR integrated platform is also used to address the need of adopting dPCR as a routine tool for personalized medicine. The dPCR platform is designed for simplified workflows, reduction in contamination potential, and rapid time-to-answer. The flexibility and utility of the novel fully integrated dPCR platform have the potential to transform personalized medicine for cancer recurrence monitoring.

Access Full Report at https://www.databridgemarketresearch.com/reports/us-polymerase-chain-reaction-market

For instance,

• In January 2022, as per an article by NCBI, the application of personalized medicine is said to be rapidly evolving and it has expanded beyond simple genomics. The researchers also stated that personalized medicines are applied to make medical decisions by integrating daily health, disease characteristic, organ function, environmental, and lifetime exposure data

It can be concluded that the increasing demand for personalized medicine is expected to drive market growth in the forecast period.

Key Findings of the Study

Increasing Application of PCR

PCR has many research and practical applications. It has been routinely used in DNA cloning, medical diagnostics, and forensic analysis of DNA. The PCR technique has become a standard diagnostic and research tool in the field of dentistry. PCR and other molecular biology techniques enable the diagnosis of infectious microbes that cause maxillofacial infections. This helps in the effective management of conditions such as periodontal disease, caries, oral cancer, and endodontic infections. It has applications in various healthcare fields, such as clinical research, genetics, and forensic science. In the field of medicine, it can help in the testing of genetic disease mutations.

With the advent of PCR-based DNA fingerprinting, PCR became an invaluable tool in forensic investigations using DNA fingerprinting, tiny fragments of DNA which can be isolated from a crime scene and compared to a huge database of DNA of convicts or criminals. It is also useful in ruling out suspects as part of an investigation.

PCR is also used in comparative studies of genomes and phylogenies. It has applications in gene expression and functional analysis. PCR is used in many areas of biology and medicine, including molecular biology research, medical diagnostics, and even some branches of ecology as well.

For instance,

• In May 2023, as per an article by NCBI, PCR is the most well-developed molecular technique up to now and has a wide range of already fulfilled, and potential, clinical applications, including specific or broad-spectrum pathogen detection, evaluation of emerging novel infections, surveillance, early detection of biothreat agents

Thus, the increasing applications of PCR are expected to drive market growth.

Report Scope and Market Segmentation

Segment Analysis

The U.S. polymerase chain reaction market is segmented into five notable segments based on product type, method, application, end user, and distribution channel.

• On the basis of product type, the market is segmented into reagents, instruments, consumables, and software and services.

In 2023, the reagents segment is expected to dominate the U.S. Polymerase Chain Reaction Marke

In 2023, the reagents segment is expected to dominate the market, growing with a CAGR of 13.0% in the forecast period of 2023 to 2030. The reagents segment is expected to dominate the market due to rising technological advancements.

• On the basis of method, the market is segmented into real-time PCR, reverse-transcriptase (RT) PCR, conventional PCR, multiplex PCR, nested PCR, hot start PCR, long-range PCR, assembly PCR, inverse PCR, and others.

In 2023, the real-time PCR segment is expected to dominate the U.S. polymerase chain reaction market

In 2023, the real-time PCR segment is expected to dominate the market, growing with a CAGR of 14.4% in the forecast period of 2023 to 2030. The real-time PCR segment is expected to dominate the market due to the integration of artificial intelligence and machine learning.

• On the basis of application, the market is segmented into clinical, life science and related researches, forensic science, environmental microbiology, and other. In 2023, the clinical segment is expected to dominate the market, growing with a CAGR of 14.2% in the forecast period of 2023 to 2030
• On the basis of end user, the market is segmented into pharmaceutical and biotechnology companies, hospitals and clinics, diagnostic laboratories, academic and research organizations, forensic laboratories, reference laboratories, and others. In 2023, the pharmaceutical and biotechnology companies segment is expected to dominate the market, growing with a CAGR of 15.1% in the forecast period of 2023 to 2030
• On the basis of distribution channel, the market is segmented into direct tender, retail sales, and others. In 2023, the direct tender segment is expected to dominate the market, growing with a CAGR of 13.9% in the forecast period of 2023 to 2030

Major Players

Data Bridge Market Research recognizes the following companies as the market players in the U.S. polymerase chain reaction market that include Beckman Coulter, Inc (U.S.),  F. Hoffmann-La Roche Ltd (Switzerland), Promega Corporation (U.S.), Illumina, Inc (U.S.), Bio-Rad Laboratories, Inc (U.S.), QIAGEN (Netherlands), Merck KGaA (U.S.), GenScript (U.S.),  Thermo Fisher Scientific Inc (U.S.), PerkinElmer Inc (U.S.), Enzo Life Sciences, Inc (U.S.), bioMérieux Inc (France), Takara Bio Inc. (Japan), LGC biosearch technologies (U.K.), Meridian bioscience Inc (U.S.), Luminex Corporation (U.S.)  and Agilent Technologies, Inc (U.S.) among others.

Market Development

• In April 2023, bioMérieux receives US FDA 510(k) clearance for the BIOFIRE SPOTFIRE Respiratory Panel Mini as it detects five of the most common viral causes of upper respiratory tract infections. This has helped the company to expand its product portfolio
• In August 2022, F. Hoffmann-La Roche Ltd launched a digital PCR system named Digital Light Cycler system. The company stated that it is designed to accurately quantify trace amounts of specific DNA and RNA targets which are not typically detectable by conventional PCR methods and will also help company in PCR portfolio expansion
• In May 2022, Agilent Technologies Inc. announced that previously CE-IVD marked instruments, kits, and reagents were released as IVDR Class A in compliance with the new EU IVDR regulation
• In March 2022, Illumina Inc company announced the launch of TruSight Oncology (TSO) Comprehensive (EU), a single test that assesses multiple tumor genes and biomarkers to reveal the specific molecular profile of a patient's cancer. The company believes this will help in expanding its product portfolio

In October 2021, Perkin Elmer Inc announced that the U.S. Food and Drug Administration (FDA) has issued Emergency Use Authorization (EUA) for the PKamp™ Respiratory SARS-CoV-2 RT-PCR Panel 1 assay. Qualified laboratories can immediately begin using this single test for the simultaneous qualitative detection and differentiation of SARS-CoV-2. This has helped the company to expand its product portfolio

For more detailed information about the U.S. polymerase chain reaction market  report, click here – https://www.databridgemarketresearch.com/reports/us-polymerase-chain-reaction-market